<DOC>
	<DOCNO>NCT02184078</DOCNO>
	<brief_summary>Study determine effect nevirapine steady state pharmacokinetics rifabutin assess steady state pharmacokinetics nevirapine give combination rifabutin</brief_summary>
	<brief_title>Study Determine Effects Nevirapine ( VIRAMUNE速 ) Steady State Pharmacokinetics Rifabutin ( MYCOBUTIN速 ) HIV+ Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Male female patient age 18 65 year seropositive HIV1 antibody ELISA test confirm alternative method e.g . Western Blot Lymphocytes Expressing CD4+ Surface Marker ( CD4+ cell count ) &gt; = 100 cells/mm続 Patients must take least 2 antiretroviral agent ( exception ritonavir , nelfinavir nonnucleoside reverse transcriptase inhibitor take continuously least 28 day prior study entry ( Day 0 ) Patients currently treat rifabutin screen period may include provided patient receive 300 mg daily ( 150 mg daily patient concomitantly take Zidovudine ( ZDV ) , saquinavir indinavir ) change dose &gt; 25 % within 28 day prior Study Day 0 Patients meet follow laboratory parameter : Granulocyte count &gt; 1000 cells/mm続 Hemoglobin &gt; 9.0 g/dl ( men woman ) Platelet count &gt; 75000 cells/mm3 Alkaline Phosphatase &lt; 3.0 time upper limit normal Serum GlutamicOxaloacetic Transaminase ( SGOT ) Serum GlutamicPyruvic Transaminase ( SGPT ) &lt; 3.0 time upper limit normal Total bilirubin &lt; 1.5 time upper limit normal Female patient childbearing potential must willing use reliable form contraception must include medically form barrier contraception Patients able provide write consent comply study requirement Female patient pregnant breastfeeding Seated systolic blood pressure 100 mmHg great 150 mmHg and/or heart rate le 50 great 90 beats/min . History drug allergy know drug hypersensitivity Patients receive investigational drug , antineoplastic agent radiotherapy local skin radiotherapy treatment within 12 week start study medication Patients require systemic treatment corticosteroid drug know hepatic enzyme inducer inhibitor within 14 day study entry ( Study Day 0 ) . Such substance thesis category include : macrolide antibiotic ( erythromycin , clarithromycin , azithromycin ) azole antifungal ( ketoconazole , fluconazole , itraconazole ) rifampin phenytoin Use ritonavir , nelfinavir nonnucleoside reverse transcriptase inhibitor within 28 day Study Day 0 trial Patients clinical evidence active tuberculosis ( TB ) undergo treatment prophylaxis TB Patients current history intravenous drug abuse , alcohol substance abuse ( within last year ) History clinically important disease include hepatic , renal , cardiovascular gastrointestinal Patients malabsorption , severe chronic diarrhea subject unable maintain adequate oral intake Patients previous antiretroviral background therapy take continuously 28 day prior study entry ( Day 0 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>